SG11202101176YA - Substituted benzimidazoles as pad4 inhibitors - Google Patents
Substituted benzimidazoles as pad4 inhibitorsInfo
- Publication number
- SG11202101176YA SG11202101176YA SG11202101176YA SG11202101176YA SG11202101176YA SG 11202101176Y A SG11202101176Y A SG 11202101176YA SG 11202101176Y A SG11202101176Y A SG 11202101176YA SG 11202101176Y A SG11202101176Y A SG 11202101176YA SG 11202101176Y A SG11202101176Y A SG 11202101176YA
- Authority
- SG
- Singapore
- Prior art keywords
- substituted benzimidazoles
- pad4 inhibitors
- pad4
- inhibitors
- benzimidazoles
- Prior art date
Links
- 150000001556 benzimidazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862715858P | 2018-08-08 | 2018-08-08 | |
PCT/US2019/045424 WO2020033488A1 (en) | 2018-08-08 | 2019-08-07 | Substituted benzimidazoles as pad4 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202101176YA true SG11202101176YA (en) | 2021-03-30 |
Family
ID=67766299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202101176YA SG11202101176YA (en) | 2018-08-08 | 2019-08-07 | Substituted benzimidazoles as pad4 inhibitors |
Country Status (18)
Country | Link |
---|---|
US (1) | US20220402950A1 (en) |
EP (1) | EP3833438B1 (en) |
JP (1) | JP7483678B2 (en) |
KR (1) | KR20210042932A (en) |
CN (1) | CN112805066A (en) |
AU (1) | AU2019318415A1 (en) |
BR (1) | BR112021002089A2 (en) |
CA (1) | CA3108871A1 (en) |
CL (1) | CL2021000292A1 (en) |
CO (1) | CO2021001219A2 (en) |
EA (1) | EA202190464A1 (en) |
ES (1) | ES2973714T3 (en) |
IL (1) | IL280641A (en) |
MX (1) | MX2021001471A (en) |
PE (1) | PE20211067A1 (en) |
SG (1) | SG11202101176YA (en) |
TW (1) | TW202019411A (en) |
WO (1) | WO2020033488A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210042935A (en) | 2018-08-08 | 2021-04-20 | 브리스톨-마이어스 스큅 컴퍼니 | Substituted thienopyrrole as a PAD4 inhibitor |
SG11202101174RA (en) | 2018-08-08 | 2021-03-30 | Bristol Myers Squibb Co | Indole and azaindole inhibitors of pad enzymes |
MX2022013615A (en) | 2020-04-30 | 2022-11-16 | Gilead Sciences Inc | Macrocyclic inhibitors of peptidylarginine deiminases. |
US11878965B2 (en) | 2020-12-22 | 2024-01-23 | Gilead Sciences, Inc. | Inhibitors of peptidylarginine deiminases |
CN116492462B (en) * | 2023-02-03 | 2023-09-22 | 山东第一医科大学附属眼科医院(山东省眼科医院) | Application of PAD4 inhibitor in preventing and treating immune rejection after cornea transplantation |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2609126T3 (en) * | 2012-07-26 | 2017-04-18 | Glaxo Group Limited | 2- (Azaindol-2-yl) benzimidazoles as PAD4 inhibitors |
EP3298003B1 (en) * | 2015-05-21 | 2023-04-19 | GlaxoSmithKline Intellectual Property Development Limited | Benzoimidazole derivatives as pad4 inhibitors |
AR107030A1 (en) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | AZA-BENCIMIDAZOL INHIBITORS OF PAD4 |
AR107032A1 (en) * | 2015-12-09 | 2018-03-14 | Padlock Therapeutics Inc | PAD4 BICYCLIC INHIBITORS |
EP3490989B1 (en) * | 2016-07-27 | 2020-09-09 | Padlock Therapeutics, Inc. | Covalent inhibitors of pad4 |
-
2019
- 2019-08-07 PE PE2021000170A patent/PE20211067A1/en unknown
- 2019-08-07 ES ES19759133T patent/ES2973714T3/en active Active
- 2019-08-07 US US17/265,844 patent/US20220402950A1/en active Pending
- 2019-08-07 WO PCT/US2019/045424 patent/WO2020033488A1/en unknown
- 2019-08-07 EP EP19759133.2A patent/EP3833438B1/en active Active
- 2019-08-07 KR KR1020217006450A patent/KR20210042932A/en active Search and Examination
- 2019-08-07 TW TW108128157A patent/TW202019411A/en unknown
- 2019-08-07 EA EA202190464A patent/EA202190464A1/en unknown
- 2019-08-07 MX MX2021001471A patent/MX2021001471A/en unknown
- 2019-08-07 SG SG11202101176YA patent/SG11202101176YA/en unknown
- 2019-08-07 AU AU2019318415A patent/AU2019318415A1/en not_active Abandoned
- 2019-08-07 BR BR112021002089-6A patent/BR112021002089A2/en not_active Application Discontinuation
- 2019-08-07 CN CN201980064958.8A patent/CN112805066A/en active Pending
- 2019-08-07 JP JP2021506621A patent/JP7483678B2/en active Active
- 2019-08-07 CA CA3108871A patent/CA3108871A1/en active Pending
-
2021
- 2021-02-03 CL CL2021000292A patent/CL2021000292A1/en unknown
- 2021-02-03 CO CONC2021/0001219A patent/CO2021001219A2/en unknown
- 2021-02-04 IL IL280641A patent/IL280641A/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP2021534097A (en) | 2021-12-09 |
TW202019411A (en) | 2020-06-01 |
CA3108871A1 (en) | 2020-02-13 |
CL2021000292A1 (en) | 2021-06-11 |
CN112805066A (en) | 2021-05-14 |
CO2021001219A2 (en) | 2021-02-17 |
AU2019318415A1 (en) | 2021-03-25 |
WO2020033488A1 (en) | 2020-02-13 |
BR112021002089A2 (en) | 2021-05-04 |
MX2021001471A (en) | 2021-04-28 |
KR20210042932A (en) | 2021-04-20 |
JP7483678B2 (en) | 2024-05-15 |
EP3833438B1 (en) | 2024-02-07 |
PE20211067A1 (en) | 2021-06-09 |
EP3833438A1 (en) | 2021-06-16 |
EA202190464A1 (en) | 2021-06-16 |
IL280641A (en) | 2021-03-25 |
US20220402950A1 (en) | 2022-12-22 |
ES2973714T3 (en) | 2024-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL278916A (en) | Benzoimidazole derivatives as pad4 inhibitors | |
RS64167B1 (en) | Benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors | |
IL254318B (en) | Benzimidazole derivatives as bromodomain inhibitors | |
IL277455A (en) | Aminopyrimidine derivatives as ctps1 inhibitors | |
IL268614B (en) | Aminotriazolopyridines as kinase inhibitors | |
IL280641A (en) | Substituted benzimidazoles as pad4 inhibitors | |
IL259796A (en) | Aza-benzimidazole inhibitors of pad4 | |
IL274207B (en) | Aminoimidazopyridazines as kinase inhibitors | |
IL258870A (en) | Substituted indazole compounds as rorgammat inhibitors and uses thereof | |
HK1257565A1 (en) | New trifluoromethylpropanamide derivatives as htra1 inhibitors | |
HK1257567A1 (en) | New difluoroketamide derivatives as htra1 inhibitors | |
HK1252767A1 (en) | Pyrazol-pyridine derivatives as eaat3 inhibitors | |
IL274821A (en) | Compounds as mpges-1 inhibitors |